Stockscreener 앱 받기
40.72
1.28%
-0.53
시간 외 거래:
40.75
0.03
+0.07%
전일 마감가:
$41.25
열려 있는:
$41.11
하루 거래량:
9.83M
Relative Volume:
1.43
시가총액:
$47.49B
수익:
$17.53B
순이익/손실:
$1.58B
주가수익비율:
30.26
EPS:
1.3457
순현금흐름:
$444.18M
1주 성능:
+3.93%
1개월 성능:
+5.17%
6개월 성능:
+28.17%
1년 성능:
+102.49%
1일 변동 폭
$40.71
$41.87
1주일 범위
$38.25
$42.02
52주 변동 폭
$18.82
$42.02
테바 ADR Stock (TEVA) Company Profile
명칭
Teva Pharmaceutical Industries Ltd Adr
전화
972 (3) 914-8213
주소
TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV
Compare TEVA vs TAK, HLN, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
40.72 | 47.49B | 17.53B | 1.58B | 444.18M | 1.3457 |
TAK
Takeda Pharmaceutical Co Adr
|
19.01 | 60.73B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.68 | 42.57B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
75.29 | 31.11B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
540.03 | 23.16B | 3.17B | 1.29B | 1.01B | 27.09 |
테바 ADR Stock (TEVA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-10-01 | 개시 | TD Cowen | Buy |
| 2026-09-23 | 개시 | Oppenheimer | Outperform |
| 2026-09-09 | 개시 | Leerink Partners | Outperform |
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-12-05 | 개시 | Scotiabank | Sector Outperform |
| 2025-06-06 | 개시 | Goldman | Buy |
| 2025-05-28 | 개시 | Truist | Buy |
| 2025-05-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-07-10 | 업그레이드 | Argus | Hold → Buy |
| 2024-03-08 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2024-02-12 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-01-23 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-01-03 | 업그레이드 | Piper Sandler | Underweight → Neutral |
| 2023-12-18 | 개시 | HSBC Securities | Buy |
| 2023-11-27 | 업그레이드 | UBS | Neutral → Buy |
| 2023-07-06 | 업그레이드 | UBS | Sell → Neutral |
| 2023-05-25 | 개시 | Morgan Stanley | Equal-Weight |
| 2023-05-18 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-01-19 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-11-14 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-11-04 | 다운그레이드 | UBS | Neutral → Sell |
| 2022-10-21 | 재개 | Jefferies | Buy |
| 2022-08-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-06-14 | 재개 | UBS | Neutral |
| 2022-05-17 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-05-04 | 다운그레이드 | Piper Sandler | Neutral → Underweight |
| 2022-04-05 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2022-03-25 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2022-01-27 | 다운그레이드 | Argus | Buy → Hold |
| 2021-10-28 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-05-04 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2020-11-25 | 개시 | Oppenheimer | Perform |
| 2020-08-06 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2020-07-27 | 재개 | Goldman | Neutral |
| 2020-06-01 | 업그레이드 | SunTrust | Hold → Buy |
| 2020-04-24 | 재개 | Citigroup | Neutral |
| 2020-04-06 | 업그레이드 | UBS | Neutral → Buy |
| 2020-02-24 | 다운그레이드 | Edward Jones | Hold → Sell |
| 2019-11-12 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2019-10-17 | 업그레이드 | Gabelli & Co | Hold → Buy |
| 2019-08-07 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-07-19 | 개시 | Wolfe Research | Peer Perform |
| 2019-07-15 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2019-07-10 | 재개 | Credit Suisse | Neutral |
| 2019-07-05 | 업그레이드 | Argus | Hold → Buy |
| 2019-06-11 | 개시 | Barclays | Underweight |
| 2019-06-03 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-05-30 | 다운그레이드 | BofA/Merrill | Buy → Underperform |
| 2019-05-28 | 다운그레이드 | UBS | Buy → Neutral |
| 2019-03-20 | 개시 | SunTrust | Hold |
| 2019-03-07 | 재개 | UBS | Buy |
모두보기
테바 ADR 주식(TEVA)의 최신 뉴스
Corcept Looks To End Teva's Mifepristone Antitrust Case - Law360
Small Molecule Active Pharmaceutical Ingredient Market Insights: Demand Trends, Competitive Landscape & Industry Outlook - EIN News
J&J Q3 Earnings Beat Estimates, Sales Miss, View Raised, Stock Down - Zacks Investment Research
ETFs Investing in Teva Pharmaceutical Industries Limited Stocks - TradingView
Teva Pharmaceutical Industries Ltd. to Host R&D Day on November 11, 2026 - Quiver Quantitative
Teva to Host R&D Day on Wednesday, November 11 in New York City - GlobeNewswire Inc.
Teva to Host R&D Day on Wednesday, November 11 in New York City - GlobeNewswire
Teva Pharmaceutical Industries (NYSE:TEVA) Stock Price Target Raised at JPMorgan Chase & Co. - MarketBeat
TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia - Zacks Investment Research
Teva Wins FDA Approval For Schizophrenia Innovation - Healthcare Digital
Teva Pharmaceutical Industries (TEVA): Transitioning from Generics to High-Margin Branded Drugs - Yahoo Finance
ETFs Investing in Teva Pharmaceutical Industries Limited Stocks - TradingView
Pretax income of Teva Pharmaceutical Industries Limited – BMV:TEVA1/N - TradingView
Teva Pharmaceutical Industries (TEVA) Stock Forecasts - Yahoo Finance
Teva Pharmaceutical Industries Ltd (HAM:TEVA) Stock Earnings Transcripts - GuruFocus
Teva Pharmaceutical Industries Ltd (HAM:TEVA) Stock Price, Trades & News - GuruFocus
Teva Pharmaceutical Industries Ltd. Advanced Charts | TEVA - Barron's
Teva Pharmaceutical Industries Ltd. Financials | TEVA - Barron's
Israeli Pharma Giant Teva Wins FDA Approval for Monthly Schizophrenia Injection Weltruza - Haaretz
Teva Pharmaceutical Industries (TEVA) Stock Forecasts - Yahoo! Finance Canada
Teva Pharmaceutical Industries Limited (TEVA) Discusses FDA Approval of Weltruza and Strategic Growth InitiativesSlideshow (NYSE:TEVA) 2026-10-09 - Seeking Alpha
Teva wins FDA approval for monthly schizophrenia injection Weltruza - Reuters
Oppenheimer Adjusts Teva Pharmaceutical Industries PT to $52 From $50, Maintains Outperform Rating - Yahoo Finance
Teva debuts Weltruza in schizophrenia as much-hyped FDA nod for long-acting olanzapine arrives - Fierce Pharma
J&J Stock Ahead of Q3 Earnings: Should You Buy, Sell or Hold? - Zacks Investment Research
Teva Pharmaceutical Industries Ltd. Research & Ratings | TEVA1N - Barron's
Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia - Teva Pharmaceuticals
Teva Pharmaceutical Industries Ltd. Company & People | TEVA - Barron's
Teva Pharmaceutical Industries (NYSE:TEVA) Stock Price - Simply Wall Street
Teva Pharmaceutical Industries (NYSE:TEVA) Stock Forecast & Analyst Predictions - Simply Wall Street
Here's Why You Should Add URGN Stock to Your Portfolio Now - Zacks Investment Research
Teva Pharmaceutical: 3 Numbers That Explain This Generic-Drug Turnaround - The Motley Fool
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Short Interest Update - MarketBeat
Is Teva Pharmaceutical Industries (TEVA) Undervalued Following New Phase 3 Schizophrenia Data? - simplywall.st
Teva, Wyeth Show How Claimed Advances Shape Enablement - Law360
Teva Pharmaceutical Industries Ltd. to Report Third Quarter 2026 Financial Results on November 3, 2026 - quiverquant.com
Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET - GlobeNewswire
Teva Releases Q3 2026 Aide Memoire - GlobeNewswire
Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET - GlobeNewswire Inc.
Teva Releases Q3 2026 Aide Memoire - GlobeNewswire Inc.
Viatris, Teva initiated at Outperform at Oppenheimer - Seeking Alpha
Teva Pharmaceutical Industries(TEVA.US) Director Sells US$14.36 Million in Common Stock - Moomoo
Teva Pharmaceutical Industries (TEVA) Stock Forecasts - finance.yahoo.com
Oppenheimer Initiates Coverage on Teva Pharmaceutical Industries (NYSE:TEVA) - MarketBeat
Teva Eyes New Growth Phase After Securing Investment-Grade Ratings - MarketBeat
Teva Eyes New Growth Phase After Securing Investment-Grade Ratings - Yahoo Finance
TEVA: Investment grade status enables accelerated innovation, robust launches, and renewed generics growth - TradingView
TEVA: Focus shifts to innovation, high-margin launches, and renewed growth in generics and biosimilars - TradingView
Brian Savage Sells 7,342 Shares of Teva Pharmaceutical Industries (NYSE:TEVA) Stock - MarketBeat
Teva Pharmaceutical Industries (NYSE:TEVA) Director Roberto Mignone Sells 367,600 Shares - MarketBeat
테바 ADR (TEVA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
테바 ADR 주식 (TEVA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| MIGNONE ROBERTO | Director |
Sep 18 '26 |
Sale |
39.06 |
367,600 |
14,356,802 |
0 |
| Bridger Management, LLC (1) | Shareholder |
Sep 18 '26 |
Proposed Sale |
39.19 |
367,600 |
14,406,244 |
0 |
| Savage Brian | Officer |
Sep 18 '26 |
Proposed Sale |
38.85 |
7,028 |
273,062 |
0 |
| Savage Brian | Interim Chief Legal Officer |
Sep 18 '26 |
Sale |
38.85 |
7,342 |
285,215 |
8,500 |
| Satchi-Fainaro Ronit | Director |
Aug 21 '26 |
Sale |
37.25 |
415 |
15,459 |
111,986 |
| Weiss Amir | Chief Accounting Officer |
Aug 21 '26 |
Option Exercise |
19.61 |
2,500 |
49,025 |
15,571 |
| Weiss Amir | Chief Accounting Officer |
Aug 21 '26 |
Sale |
37.62 |
9,445 |
355,301 |
13,071 |
| Lippman Evan | EVP, Business Development |
Aug 17 '26 |
Sale |
36.57 |
18,600 |
680,291 |
25,591 |
| Lippman Evan | Officer |
Aug 17 '26 |
Proposed Sale |
36.57 |
18,600 |
680,291 |
0 |
| Zaks Tal Zvi | Director |
Aug 05 '26 |
Sale |
34.87 |
17 |
593 |
73,247 |
2.54%
0.62%
자본화:
|
볼륨(24시간):